Acrivon Therapeutics, Inc. Common Stock (ACRV) has a negative trailing P/E of -0.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -137.62%.
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2020 | -40.5 | 0.00 | -25.53 | 0.00 | - |
| 2021 | -13.2 | -0.06 | -9.02 | 0.00 | - |
| 2022 | -8.1 | -0.64 | 1.48 | 0.00 | - |
| 2023 | -1.8 | -0.02 | 0.90 | 0.00 | - |
| 2024 | -2.9 | 0.12 | 1.30 | 0.00 | - |
| 2025 | -1.2 | 0.31 | 0.82 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2020 | $-0.25 | $0.00 | $-5.31M | - |
| 2021 | $-0.78 | $0.00 | $-16.24M | - |
| 2022 | $-1.35 | $0.00 | $-29.68M | - |
| 2023 | $-2.74 | $0.00 | $-60.39M | - |
| 2024 | $-0.24 | $0.00 | $-80.56M | - |
| 2025 | $-2.02 | $0.00 | $-77.91M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.10 | $-2.49 – $-1.78 | $1.31M | $1.31M – $1.31M | 6 |
| 2027 | $-1.95 | $-2.46 – $-1.24 | $3.8M | $3.8M – $3.8M | 5 |
| 2028 | $-2.12 | $-4.25 – $-0.71 | $21.38M | $21.38M – $21.38M | 5 |
| 2029 | $-1.75 | $-1.75 – $-1.75 | $70.65M | $70.65M – $70.65M | 1 |
| 2030 | $-0.97 | $-0.97 – $-0.97 | $144.13M | $144.13M – $144.13M | 1 |
